Regulations & Compendial Methods on Temple Quality in Pharma Course

ICH Q1 — Stability Testing

Sun, 06 Sep 2026 00:00:00 +0000

The one idea

A shelf life is a hypothesis: this product, in this package, stored this way, still meets its specification for N months. Stability testing is the experiment that tests that hypothesis over real time. ICH Q1 is the agreed protocol for running that experiment so that the result means the same thing to every regulator.

This is Lecture 1’s definition of science made concrete — you state a claim, you expose it to testing, and you are obligated to revise the shelf life (or the storage statement, or the formulation) when the data say so.

ICH Q2 — Validation of Analytical Procedures

Sun, 06 Sep 2026 00:00:00 +0000

Outline and talking points — the full write-up is still to come.

What this page covers

The validation characteristics: specificity, accuracy, precision (repeatability / intermediate precision / reproducibility), detection limit, quantitation limit, linearity, range.
Which characteristics are required for which test type (identification, assay, impurities — quantitative vs. limit, dissolution).
Q2(R2) (2023): explicit coverage of multivariate methods and a stronger link to Q14 — validation as the confirmation of an analytical target profile, not a box-check after the fact.
The tie to Q1: a method used on stability must be validated as stability-indicating (demonstrated via forced degradation).

Lecture prep — open items

Worked example: a validation protocol + acceptance criteria for an HPLC assay.
Contrast small-molecule assay validation with a potency bioassay for a biologic.
Decide depth on statistics (regression diagnostics, %RSD expectations by concentration).

ICH Q3 — Impurities

Sun, 06 Sep 2026 00:00:00 +0000

Outline and talking points — the full write-up is still to come.

What this page covers

Q3A(R2) — impurities in new drug substances: reporting / identification / qualification thresholds tied to maximum daily dose.
Q3B(R2) — degradation products in new drug products (the ones Q1 stability testing tracks).
Q3C(R9) — residual solvents: Class 1 (avoid), Class 2 (limit, PDE-based), Class 3 (low toxic potential).
Q3D(R2) — elemental impurities: the permitted daily exposure model and the risk assessment that replaced USP <231> heavy metals.
Related: M7 — mutagenic impurities (the “cousin” of Q3 the class should know exists).

Lecture prep — open items

The thresholds table, with a dosing example students compute themselves.
How a Q3 threshold becomes a specification limit becomes a required method sensitivity (LOQ).
Q3D risk assessment walkthrough for a real dosage form.

ICH Q6 — Specifications

Sun, 06 Sep 2026 00:00:00 +0000

Outline and talking points — the full write-up is still to come.

What this page covers

What a specification is: a list of tests, references to analytical procedures, and acceptance criteria — the contract for release.
Q6A — small molecules: universal tests (description, identification, assay, impurities) plus dosage-form-specific tests (dissolution, uniformity, water, etc.); decision trees.
Q6B — biotech / biologics: identity, purity and impurities (product-related vs. process-related), potency, quantity — and why heterogeneity is expected, not a defect.
The idea of acceptance criteria as a hypothesis: set from clinical/stability experience, revised as knowledge grows (links to Q1 and Q8–Q12 lifecycle).

Lecture prep — open items

Side-by-side: a small-molecule tablet spec vs. a monoclonal antibody spec.
Walk one Q6A decision tree (e.g. when is a dissolution test required, and what kind).
How specification limits get tightened or widened post-approval, and the regulatory mechanism for it.

ICH Q7 — GMP for Active Pharmaceutical Ingredients

Sun, 06 Sep 2026 00:00:00 +0000

Outline and talking points — the full write-up is still to come.

What this page covers

Where GMP starts in an API process (and the table that tells you).
The laboratory controls section: approved procedures, instrument qualification and calibration, out-of-specification (OOS) investigations, reference standards, certificates of analysis.
Documentation and data integrity — ALCOA+, audit trails, contemporaneous records.
On-going stability program obligations (connects to Q1).
Q7 as the floor the whole quality system stands on — the Q8–Q12 lifecycle ideas sit on top of it.

Lecture prep — open items

Anatomy of an OOS investigation (Phase I lab assessment → Phase II).
A redacted real Form 483 / warning letter citing lab-control failures — discuss.
What “the data is the record” means in practice for an analyst.

ICH Q8–Q12 — Development, Risk, Quality System & Lifecycle

Sun, 06 Sep 2026 00:00:00 +0000

Outline and talking points — the full write-up is still to come. (Grouped by design — for an analysis course these are context; split into separate pages later if the class needs the depth.)

What this page covers

Q8 — pharmaceutical development: quality by design (QbD), critical quality attributes (CQAs), design space, control strategy.
Q9(R1) — quality risk management: FMEA and friends, and the formality/subjectivity revisions.
Q10 — the pharmaceutical quality system: management responsibility, CAPA, change management, management review; how it maps onto ICH’s model.
Q11 — development and manufacture of drug substances (small molecule and biotech); starting-material justification.
Q12 — lifecycle management: established conditions, the Product Lifecycle Management (PLCM) document, post-approval change categories.
The analytical throughline: CQAs drive specifications drive methods; a method is part of the control strategy, and changing it is a managed change under Q10/Q12.

Lecture prep — open items

One clean QbD diagram: QTPP → CQAs → CPPs → control strategy.
Decide whether Q11 gets real time or a mention.
Q12 “established conditions” for an analytical procedure — worked example.

ICH Q13 — Continuous Manufacturing

Sun, 06 Sep 2026 00:00:00 +0000

Outline and talking points — the full write-up is still to come.

What this page covers

What “continuous” changes: no discrete batch step, so residence time distribution, state of control, and material traceability become the control strategy.
Process analytical technology (PAT) — NIR, Raman, in-line UV — moving the measurement onto the line.
Real-time release testing (RTRT) — releasing product on process and in-line data instead of (or alongside) end-product testing.
Batch definition, startup/shutdown, and diversion of non-conforming material.
The analytical shift: from “take a sample to the lab” to “the line measures itself, and the analyst validates and monitors the model.”

Lecture prep — open items

Pair with Q14 — PAT methods need the same lifecycle rigor.
A real RTRT example (e.g. a CM tablet line) if one is publicly documented.
Chemometric model maintenance — what happens when the feed material drifts.

ICH Q14 — Analytical Procedure Development

Sun, 06 Sep 2026 00:00:00 +0000

Outline and talking points — the full write-up is still to come. (This one is close to the core of the course — likely deserves depth on par with Q1.)

What this page covers

The Analytical Target Profile (ATP) — the performance the method must deliver, defined before development.
Minimal vs. enhanced approaches to method development.
Method Operable Design Region (MODR) — the analytical analogue of a design space; robustness studied by DOE, not discovered by accident.
Method lifecycle — development → qualification/validation (Q2(R2)) → continued performance verification → managed change (Q12 established conditions).
Why Q14 reframes everything in this section: the method is designed against its requirements, and Q2 validation confirms the design rather than testing a method built by guesswork.
Ties to Q13 — PAT and RTRT methods are developed under exactly this framework.

Lecture prep — open items

ATP worked example for an impurity method.
A robustness DOE the class can interpret (main effects + interactions on resolution).
Decide: is this a full lecture on its own, or paired with Q2?